Pulmonary Complications of Cancer: Difference between revisions

No edit summary
No edit summary
Line 9: Line 9:
Bacterial infection in cancer patients present in the form of pneumonia. The severity of bacterial pneumonia depends on the underlying immunologic defect, the duration of the immunocompromised state, whether the infection is community acquired or hospital acquired and the pathogen involved.<ref name=":1">Stover, D.E. and Kaner, R.J. (1996), Pulmonary complications in cancer patients. CA: A Cancer Journal for Clinicians, 46: 303-320. doi:10.3322/canjclin.46.5.303 Available at https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/canjclin.46.5.303</ref>
Bacterial infection in cancer patients present in the form of pneumonia. The severity of bacterial pneumonia depends on the underlying immunologic defect, the duration of the immunocompromised state, whether the infection is community acquired or hospital acquired and the pathogen involved.<ref name=":1">Stover, D.E. and Kaner, R.J. (1996), Pulmonary complications in cancer patients. CA: A Cancer Journal for Clinicians, 46: 303-320. doi:10.3322/canjclin.46.5.303 Available at https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/canjclin.46.5.303</ref>


Common bacterial pathogens<ref name=":1" />:
Common bacterial pathogens<ref name=":1" /><ref name=":2">Wong JL, Evans SE. Bacterial Pneumonia in Patients with Cancer: Novel Risk Factors and Management. ''Clin Chest Med''. 2017;38(2):263-277. doi:10.1016/j.ccm.2016.12.005. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424613/</ref>:
* Streptococcus pneumoniae
* Streptococcus pneumoniae
* Haemophilus influenzae
* Haemophilus influenzae
Line 41: Line 41:


=== Protozoal Infection ===
=== Protozoal Infection ===
Pneumocystis Cariniii Pneumonia
Pneumocystis Carinii Pneumonia


== Non-Infectious Complications ==
== Non-Infectious Complications ==
Line 52: Line 52:
* Nodular
* Nodular
* Lymphangitic carcinomatosis- interstitial form of pulmonary metastasis and can occur unilaterally or bilaterally. it can present with persistent dry cough and dyspnea.
* Lymphangitic carcinomatosis- interstitial form of pulmonary metastasis and can occur unilaterally or bilaterally. it can present with persistent dry cough and dyspnea.
Pulmonary effusion is a common extrapulmonary minfestation of metastatic disease and can affect lung volumes.
Pulmonary effusion is a common extrapulmonary manifestation of metastatic disease and can affect lung volumes.


=== Obstructive Lung Disease ===
=== Obstructive Lung Disease ===
Line 60: Line 60:


=== Restrictive Lung Disease ===
=== Restrictive Lung Disease ===
Restricive lung disease can be a result of:
Restrictive lung disease can be a result of:
* Primary malignancy
* Primary malignancy
* Malignant pleural effusion
* Malignant pleural effusion
Line 80: Line 80:
Thromboembolism- due to hypercoagulabity of the blood
Thromboembolism- due to hypercoagulabity of the blood


Tumor emboli- due to microemboli involving small aretries, arterioles and capillaries
Tumor emboli- due to microemboli involving small arteries, arterioles and capillaries


Increased risk of pulmonary thromboembolism with:
Increased risk of pulmonary thromboembolism with:
Line 90: Line 90:
* Colorectal cancer
* Colorectal cancer
* Other digestive system cancer
* Other digestive system cancer
* Patients recieving cytotoxic chemotherapy
* Patients receiving cytotoxic chemotherapy
* Tamoxifen
* Tamoxifen
* Central venous catheters
* Central venous catheters
Line 98: Line 98:
=== Drug Toxicities ===
=== Drug Toxicities ===
Certain drugs have been shown to increase the risk for the development of pulmonary complications such as respiratory failure.<ref name=":0">Brown, Anne Rain; Bruno, Jeffrey; Nates, Joseph 1239: PULMONARY COMPLICATIONS IN CANCER PATIENTS: NOVEL DRUGS WITH NEW TOXICITIES, Critical Care Medicine: January 2018 - Volume 46 - Issue 1 - p 603 doi: 10.1097/01.ccm.0000529242.93804.d6 Available at https://journals.lww.com/ccmjournal/Citation/2018/01001/1239__PULMONARY_COMPLICATIONS_IN_CANCER_PATIENTS_.1193.aspx</ref> This include tyrosine kinase inhibitors, mTOR kinase inhibitors, monoclonal antibody, taxanes.  A study showed that exposure to one of more of these medications was a significant risk factor in the development of respiratory failure.<ref name=":0" />
Certain drugs have been shown to increase the risk for the development of pulmonary complications such as respiratory failure.<ref name=":0">Brown, Anne Rain; Bruno, Jeffrey; Nates, Joseph 1239: PULMONARY COMPLICATIONS IN CANCER PATIENTS: NOVEL DRUGS WITH NEW TOXICITIES, Critical Care Medicine: January 2018 - Volume 46 - Issue 1 - p 603 doi: 10.1097/01.ccm.0000529242.93804.d6 Available at https://journals.lww.com/ccmjournal/Citation/2018/01001/1239__PULMONARY_COMPLICATIONS_IN_CANCER_PATIENTS_.1193.aspx</ref> This include tyrosine kinase inhibitors, mTOR kinase inhibitors, monoclonal antibody, taxanes.  A study showed that exposure to one of more of these medications was a significant risk factor in the development of respiratory failure.<ref name=":0" />
== Diagnosis ==
Diagnostic Imaging usually used to diagnose and assess cancer patients of their pulmonary complications include:
Chest Radiographic Imaging<ref name=":2" />
High- Resolution CT Scan<ref name=":2" />
PET Scan<ref name=":2" />
Diagnostic bronchoscopy<ref name=":2" />


== Rehabilitation Treatment ==
== Rehabilitation Treatment ==

Revision as of 11:45, 1 August 2020

Original Editor - Donald John Auson Top Contributors - Donald John Auson and Kim Jackson
This article or area is currently under construction and may only be partially complete. Please come back soon to see the finished work! (1/08/2020)

Infectious Complications[edit | edit source]

Cancer patients are susceptible to infection, particularly those undergoing chemotherapy and radiation therapy. Aside from that, there are a variety of factors that predisposes the cancer patient to infection such as immune deficiencies, organ dysfunction, concurrent illness and past infections, nutritional status, psychological stress, surgery and diagnostic and invasive procedures.[1]

Bacterial Infection[edit | edit source]

Bacterial infection in cancer patients present in the form of pneumonia. The severity of bacterial pneumonia depends on the underlying immunologic defect, the duration of the immunocompromised state, whether the infection is community acquired or hospital acquired and the pathogen involved.[2]

Common bacterial pathogens[2][3]:

  • Streptococcus pneumoniae
  • Haemophilus influenzae
  • Pseudomonas aeruginosa
  • Escherichia coli
  • Klebsiella species
  • Legionella pneumophila
  • Mycoplasma pneumoniae
  • Nocardia and Actinomyces species
  • Moraxella catarrhalis

Viral Infection[edit | edit source]

Viruses that causes pneumonia in immunocompromised cancer patients include:

  • Cytomegalovirus
  • Varicella-zoster
  • Herpes simplex
  • Respiratory syncytial virus
  • Adenovirus
  • Influenza virus

Fungal Infection[edit | edit source]

Common opportunistic fungi include:

  • Aspergillus species
  • Mucor species
  • Candida species

Pathogenic fungi include:

  • Cryptococcus neoformans
  • Histoplasma capsulatum
  • Coccidioides immitis
  • Blastomyces dermatitides

Protozoal Infection[edit | edit source]

Pneumocystis Carinii Pneumonia

Non-Infectious Complications[edit | edit source]

Cancer patients can suffer from pulmonary complications not caused by infections. these complications can be result of primary malignancy, metastasis or treatment.

Metastatic Disease[edit | edit source]

Metastatic disease pertains to the complication of cancer wherein the cancer cells have spread to either a distant site or an adjacent structure. Metastasis to the lungs can happen through hematogenous, lymphatic or direct invasion.[4]

Pulmonary metastasis can occur as:

  • Nodular
  • Lymphangitic carcinomatosis- interstitial form of pulmonary metastasis and can occur unilaterally or bilaterally. it can present with persistent dry cough and dyspnea.

Pulmonary effusion is a common extrapulmonary manifestation of metastatic disease and can affect lung volumes.

Obstructive Lung Disease[edit | edit source]

  • Acute bronchospastic reaction
  • Airway tumor
  • Pre-existing COPD

Restrictive Lung Disease[edit | edit source]

Restrictive lung disease can be a result of:

  • Primary malignancy
  • Malignant pleural effusion
  • Kyphoscoliosis- can be a result of metastatic lesions to the thoracic spine or osteoporosis from treatment of the primary malignancy
  • Neuromuscular disease complications- usually associated with Lambert-Eaton Myesthenic Syndrome, which is usually associated with small cell lung cancer ~60%.
  • Phrenic nerve paralysis- can be a result of extrathoracic tumors (rare), primary lung tumor (more frequent), mediastinal tumor, surgery (lung or radical neck dissection), toxicity from chemotheraphy (5-fluorouracil or doxorubicin).
  • Pulmonary fibrosis- from radiation and chemotherapy

Restrictive lung disease from the said conditions can produce symptoms such as dyspnea and can lead to respiratory failure.

Radiation Therapy Complications[edit | edit source]

Radiation Pneumonitis

Chemotherapy Complications[edit | edit source]

Chemotherapy Pneumonitis

Pulmonary Vascular Disease[edit | edit source]

Pulmonary embolism

Thromboembolism- due to hypercoagulabity of the blood

Tumor emboli- due to microemboli involving small arteries, arterioles and capillaries

Increased risk of pulmonary thromboembolism with:

  • Pancreatic cancer
  • Lymphoma
  • Malignant brain tumors
  • Liver cancer
  • Leukemia
  • Colorectal cancer
  • Other digestive system cancer
  • Patients receiving cytotoxic chemotherapy
  • Tamoxifen
  • Central venous catheters
  • History of thromboembolism
  • Surgical procedures

Drug Toxicities[edit | edit source]

Certain drugs have been shown to increase the risk for the development of pulmonary complications such as respiratory failure.[5] This include tyrosine kinase inhibitors, mTOR kinase inhibitors, monoclonal antibody, taxanes.  A study showed that exposure to one of more of these medications was a significant risk factor in the development of respiratory failure.[5]

Diagnosis[edit | edit source]

Diagnostic Imaging usually used to diagnose and assess cancer patients of their pulmonary complications include:

Chest Radiographic Imaging[3]

High- Resolution CT Scan[3]

PET Scan[3]

Diagnostic bronchoscopy[3]

Rehabilitation Treatment[edit | edit source]

Patients with pulmonary complications can undergo pulmonary rehabilitation. Chest physiotherapy techniques can be done to alleviate symptoms and improve respiration. Some chest physiotherapy techniques that can be done are:

  • Percussions
  • Vibrations
  • Postural drainage
  • Mobilization of patient
  • Deep breathing exercises
  • Segmental breathing exercises
  • Coughing exercises

Considerations[edit | edit source]

Precautions must be made especially when treating patients with attachments, such as drains, as well as those with recent surgery to the chest. Probable osteoporosis, bony metastasis and primary malignancy over the chest area must be ruled out before performing percussions. If percussion is contraindicated to the case of the patient, other techniques can be applied such as vibrations, postural drainage, deep breathing exercises, and coughing exercises.

References[edit | edit source]

  1. Stosor V, Zembower TR, editors. Infectious Complications in Cancer Patients. Springer; 2014.
  2. 2.0 2.1 Stover, D.E. and Kaner, R.J. (1996), Pulmonary complications in cancer patients. CA: A Cancer Journal for Clinicians, 46: 303-320. doi:10.3322/canjclin.46.5.303 Available at https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/canjclin.46.5.303
  3. 3.0 3.1 3.2 3.3 3.4 Wong JL, Evans SE. Bacterial Pneumonia in Patients with Cancer: Novel Risk Factors and Management. Clin Chest Med. 2017;38(2):263-277. doi:10.1016/j.ccm.2016.12.005. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424613/
  4. Jamil A, Kasi A. Cancer, Metastasis to the Lung. [Updated 2020 Mar 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553111/
  5. 5.0 5.1 Brown, Anne Rain; Bruno, Jeffrey; Nates, Joseph 1239: PULMONARY COMPLICATIONS IN CANCER PATIENTS: NOVEL DRUGS WITH NEW TOXICITIES, Critical Care Medicine: January 2018 - Volume 46 - Issue 1 - p 603 doi: 10.1097/01.ccm.0000529242.93804.d6 Available at https://journals.lww.com/ccmjournal/Citation/2018/01001/1239__PULMONARY_COMPLICATIONS_IN_CANCER_PATIENTS_.1193.aspx